Instrument Inactif

Autres langues Celyad SA Other OTC

Actions

CLYYF

BE0974260896

Recherche biotechnologique et médicale

Autres langues

27/09	Argenx trekt Bel20 in het rood
24/09	Kleiner verlies voor Celyad
23/09	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2026
23/09	Celyad Oncology : Reports First Half Year 2026 Results
21/09	Bedrijfskalender van 21 tot 25 september 2026
28/07	Celyad Oncology : Publication of a transparency notification received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)
18/07	Rustige start cijferseizoen in Brussel
14/07	Celyad Oncology SA announced that it expects to receive ?0.5 million in funding from Fortress Investment Group LLC
14/07	Celyad kondigt private plaatsing van 500.000 euro aan
14/07	Celyad Oncology to Raise Funds via Private Placement
14/07	Celyad Oncology : Announces €500,000 Private Placement
20/05	Celyad Oncology : AGM Minutes - informal translation EN
15/04	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026
02/04	Winst voor Celyad ondanks financiele problemen
02/04	Celyad Oncology : reports full year 2025 financial results and business highlights
02/04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025
22/02	Azelis en Umicore onderuit na cijfers
15/02	Chemie beleeft sterke week in Brussel
12/02	Celyad Oncology verkoopt C-CATHez-katheter
30/09/25	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million
29/09/25	Celyad Oncology announces research facility divestiture
29/09/25	Celyad Oncology stoot onderzoeksfaciliteit af
29/09/25	Celyad Oncology : Announces Research Facility Divestiture
29/09/25	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.
28/09/25	Farma onder druk in Brussel door dreiging van nieuwe importsancties